BIA biotech manifesto 2019

In the third part of our series on Industrial Strategy, Lewis Miles and Maddie Cass provide a deep dive into the Digital and Technologies Sector Plan, analysing how these policies aim to foster growth in the UK's life sciences and engineering biology sectors. We also look forward to strengthening relations and gaining key insight from our US sister organisation with BIO's upcoming UK visit.

In this blog, Emma Lawrence, Head of Data Tech Policy and Public Affairs at BIA, explains why BIA is publishing a health data access industry checklist to support data access.

This is the first-ever autoimmunity study to evaluate a potential functional cure that targets the antigenic source – the origin of autoimmune disease.

First non-hormonal menopause treatment approved for use in the UK by the MHRA, with early-stage development at Stevenage Bioscience Catalyst

Research conducted by Pioneer Group in collaboration with Beauhurst into the UK life sciences landscape reveals a growing trend of investment into more mature companies.

Microbiotica announces that patient recruitment is complete in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.